ABSTRACT
OBJECTIVES: This study evaluated a novel approach to the delivery of directly observed therapy (DOT) for tuberculosis in Haiti. METHODS: A total of 194 patients (152 HIV seropositive, 42 HIV seronegative) received daily unsupervised triple-drug therapy for 4 to 8 weeks, followed by twice-weekly 2-drug therapy for the remainder of the 6-month period. DOT was deferred until initiation of the twice-weekly phase. RESULTS: A total of 169 of 194 patients (87.1%) completed the 6-month course. The program of deferred DOT had an effectiveness of 85%. Overall cost was reduced by approximately 40%. CONCLUSIONS: Flexible approaches to DOT, integrating behavioral knowledge, cost considerations, and practicality may improve completion rates and program effectiveness.
Subject(s)
Antitubercular Agents/administration & dosage , HIV Seropositivity , Patient Compliance , Tuberculosis, Pulmonary/drug therapy , Adult , Antitubercular Agents/economics , Comorbidity , Cost-Benefit Analysis , Drug Administration Schedule , Endemic Diseases , HIV Infections/epidemiology , Haiti/epidemiology , Humans , Middle Aged , Program Evaluation , Tuberculosis, Pulmonary/economics , Tuberculosis, Pulmonary/epidemiologySubject(s)
HIV Infections/epidemiology , Tuberculosis, Pulmonary/epidemiology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/epidemiology , Adolescent , Adult , Antibiotics, Antitubercular/therapeutic use , Antitubercular Agents/therapeutic use , Female , HIV Infections/complications , HIV Seropositivity/complications , HIV Seropositivity/epidemiology , Haiti/epidemiology , Humans , Inpatients , Male , Middle Aged , Outpatients , Rural Population , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/drug therapy , Urban PopulationABSTRACT
AIDS is inexorably involving all parts of the country and all strata of society, with 10% of the urban and 3% of the rural population infected with HIV. It is increasingly a disease of women and children. The major cofactors for transmission are also sexually transmitted. For most developing countries, in spite of all education efforts, the "silent epidemic" of AIDS continues. AIDS is known but not understood; counselling modifies behavior in only 10-20% of at-risk persons. Under optimal conditions, HIV discordant females have seroconversion rates of 4.7% per year and pregnancy rates of 10.4% per year. The recent political unrest in Zaire and Haiti will further enhance the spread of AIDS in these countries. Despite these difficult periods, the work can and must continue. After all, during our 10th year of collaboration with a Haitian private research group, the Haitian government and Cornell University, Haiti has known seven different political rulers. Finally, I want to make a pledge on behalf of the millions of people who face a certain death from HIV infection and AIDS and who will never make the front page of any newspaper. For these people, you can make a difference. You must give us the tools to carry on this fight. The clinical trials must be done where they are most needed: the developing countries. Vaccines represent the only viable alternative despite the recognized obstacles of viral heterogeneity, immunogenicity, and delivery.
